SCHEMBL3976152

SCHEMBL3976152

CCOC(=O)c1ccc(OC)c(-c2ccccc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HSD17B2 P37059 1/20 0.58
CTSA P10619 1/20 0.52
MAPT P10636 5/20 0.50
GAA P10253 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CDC25B P30305 1/20 0.50
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBA3C P0DPH7 1/20 0.49
TUBA1B P68363 1/20 0.49
TUBA4A P68366 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28657616 0.86 HSD17B2 (0.56) NPC1RAB9ASMN1; SMN2HSD17B2MAPT
SCHEMBL35823 0.85 PTGS2 (0.58) NPC1RAB9ASMN1; SMN2CTSAMAPT
SCHEMBL29918535 0.82 MAPT (0.64) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL28740395 0.82 TSHR (0.54) NPC1RAB9ASMN1; SMN2MAPTGAA
SCHEMBL14241376 0.82 SMN1; SMN2 (0.60) NPC1RAB9ASMN1; SMN2CTSAMAPT
SCHEMBL4146550 0.82 MAPT (0.55) NPC1RAB9ASMN1; SMN2HSD17B2MAPT
SCHEMBL402416 0.82 CA12 (0.62) RAB9ACTSAKMT2AALDH1A1HTT
SCHEMBL31336539 0.81 RAB9A (0.63) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL3586442 0.81 RAB9A (0.53) NPC1RAB9ASMN1; SMN2MAPTGAA
SCHEMBL9488109 0.81 CA12 (0.66) NPC1RAB9ASMN1; SMN2HSD17B2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 NPC1 1584/4885RAB9A 2501/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.